覃文新 Wenxin Qin

Researcher at Shanghai Cancer Institute. Bachelor of Science in Biochemistry from Wuhan University Department of Biology, Master of Medicine from Soochow Medical College, Doctor of Medical Science from Shanghai Medical University. Visiting Scholar at the Institute for Systems Biology (USA). Associate Editor of Hepatology Communications journal of the American Association for the Study of Liver Diseases. Has successively led National 863 Program, National 973 Program, National Science and Technology Major Projects, and National Natural Science Foundation Key International Cooperation Projects. Has published over 120 papers in academic journals such as Lancet Oncology, Nature, Nature Communications, Gastroenterology, and Hepatology. Representative works include: discovery that secreted protein DKK1 combined with alpha-fetoprotein can improve the diagnosis rate of hepatocellular carcinoma (Lancet Oncology 2012); revealed that RCAN1.4 is a novel liver cancer suppressor molecule, and its downregulation can activate the CaN/NFAT signaling pathway in liver cancer cells, thereby upregulating the secretion of cytokines IGF1 and VEGFA, forming a pro-cancer microenvironment and promoting malignant progression of liver cancer (Gastroenterology 2017); explored the stepwise precision treatment strategy for liver cancer using tumor cell mutation-specific induction of liver cancer cell senescence, followed by targeted clearance of senescent cancer cells without harming normal cells (Nature 2019); discovered that for EGFR-high-expressing liver cancer patients who are ineffective to lenvatinib treatment, combined application of EGFR inhibitors can effectively inhibit liver cancer progression (Nature 2021, cover article). Published 1 academic translation “Tumor Microenvironment” and co-edited 1 English work “Primary Liver Cancer”. Obtained 2 US patents and 3 Chinese invention patents. Research directions: tumor molecular mechanisms, tumor microenvironment, tumor therapy.

1. Zhou Y, Wang S, Wu W, Ling J, Li H, Jia Q, Zheng J, Zheng X, Yu R, Wu Q, Shi Y, Lieftink C, Beijersbergen RL, Yuan S*, Bernards R*, Jin H*, Qin W*. Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer. EBioMedicine. 2023 Jan;87:104397.
2. Wang C*, Cao Y, Yang C, Bernards R*, Qin W*. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021 Oct;18(10):690-704.
3. Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H, Cheng Z, Tao X, Yu C, Li B, Yang C, Wang S, Lv Y, Zhao F, Yao M, Cong W, Wang C, Qin W. PGC1α suppresses metastasis of HCC by inhibiting Warburg effect via PPARγ-dependent WNT/β-catenin/PDK1 axis. Hepatology. 2021 Feb;73(2):644-660.